Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-03

FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

The FDA approved a supplemental application from Prasco Laboratories to market a fixed-dose combination tablet of dapagliflozin and metformin hydrochloride. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dapagliflozin and metformin hydrochloride (dapagliflozin and metformin hydrochloride)

Snippet

SUPPL AP for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)